<DOC>
	<DOC>NCT02166177</DOC>
	<brief_summary>'ThRIL' aims to explore the feasibility, safety and efficacy of TR002, a regulatory cell therapy, as adjunct immunosuppressive treatment in the context of liver transplantation</brief_summary>
	<brief_title>Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients</brief_title>
	<detailed_description>Stage I: To evaluate the safety of administering TR002 to liver transplant recipients. Stage II: To evaluate the efficacy of TR002 administration in allowing for the discontinuation of immunosuppressive therapy in liver transplant recipients.</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<criteria>Able to give informed consent adult patients with endstage liver disease listed for primary liver transplant; calculated MELD score â‰¤ 25 at time of transplantation HIV or RNApositive Hepatitis C Virus infection; autoimmune liver disease previous organ transplant Ebstein Virus and/or Cytomegalovirus seronegativity chronic use of systemic immunosuppressants hepatocellular carcinoma outside Milano criteria leukocytes &lt;1.5x10^9/L and/or platelets &lt;50x10^9/L.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>